Lv Y, Chen M, Wang H, Zou D, Jiang X, Wang R, Jin D, Lam E, Shao S, Liu Q, Yan J, Wang X, Chen P
Kwok SP, Lam SC, et al.: prospective randomised trial. Lancet. 2004;363:1187–1192.5. Guillou PJ
40%~50%的患者为未明确的中间组,经常由于其潜在危险因素和并发症接受和HFrEF类似的以指南为导向的药物治疗。LAM等[6]学者认为,LVEF为40%~49%的心力衰竭患者占心力衰竭患者的10
药物剂量,或改为单抗治疗。(证据等级:低)文献索引:Jack Wei Chieh Tan, Derek P Chew, Kin Lam Tsui, et al.-Pacific Region
Pediatrics 2011;128:e1155–63. 13Shatrov JG, Birch SC, Lam LT, Quinlivan JA, McIntyre S, Mendz GL
阴性。🔖体液免疫特定蛋白检测^总IgE测定:免疫球蛋白A:5.2g/L↑;补体C3:0.514g/L↓;免疫球蛋白E:679IU/mL↑;KAP轻链:3.82g/L↑;LAM轻链:2.65g/L↑;β